-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
ZIKV-IN-5
| Category | Virus Protease |
| Description | ZIKV-IN-5 (compound 5c) is a low-cytotoxicity and acid-stable anti-ZIKV agent (EC50=0.71 μM). ZIKV-IN-5 effectively inhibits the activity of ZIKV NS5 MTase. |
Product Information
| Molecular Weight | 583.83 |
| Molecular Formula | C36H45NO4Si |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| In Vitro | ZIKV-IN-5 (0-200 μM; 96 h) shows low cytotoxicity. Cell Cytotoxicity Assay Cell Line: Vero cells Concentration: 0-200 Incubation Time: 96 Result: Exhibited low cytotoxicities with a CC50 value of more than 200 . |
| In Vivo | ZIKV-IN-5 (0-200 μM; 96 h) shows low cytotoxicity. |
| Target | EC50:0.71 μM (ZIKV) |
